#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Case report of relapsing COVID-19 infection in a patient with multiple sclerosis treated with ocrelizumab


Authors: J. Pazderková 1;  H. Bartoš 1,2;  P. Dlouhý 1;  M. Vachová 3,4
Authors‘ workplace: Infekční oddělení, Masarykova nemocnice, Krajská zdravotní a. s., Ústí nad Labem 1;  3. LF UK, Praha 2;  RS centrum, Neurologické oddělení, Nemocnice Teplice, Krajská zdravotní a. s., Teplice 3;  1. LF UK, Praha 4
Published in: Cesk Slov Neurol N 2021; 84/117(1): 92-94
Category: Letter to Editor
doi: https://doi.org/10.48095/cccsnn202192


Sources

1. Giovannoni G, Hawkes C, Lechner-Scott J et al. The COVID-19 pandemic and the use of MS disease--modifying therapies. Mult Scler Relat Disord 2020; 39: 102073. doi: 10.1016/j.msard.2020.102073.

2. Mehta P, McAuley DF, Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033–1034. doi: 10.1016/S0140-6736 (20) 30628-0.

3. Dabiao C, Wenxiong X, Ziying L et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report. Int J Infect Dis 2020; 93: 297–299. doi: 10.1016/j.ijid.2020.03.003.

4. Syed YY. Ocrelizumab: a review in multiple sclerosis. CNS Drugs 2018; 32 (9): 883–890. doi: 10.1007/s40263-018-0568-7.

5. Novi G, Mikulska M, Briano F et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord 2020; 42: 102120. doi: 10.1016/j.msard.2020.102120.

6. Louapre C, Collongues N, Stankoff B et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 2020; 77 (9): 1079–1088. doi: 10.1001/jamaneurol.2020.2581.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 1

2021 Issue 1

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#